Figure 2

(a) Parasite count distribution of P. knowlesi clinical samples and corresponding test outcomes, grouped according to antimalarial treatment status at sampling point, further sub-grouped by pilot and validation testing phases; horizontal dotted line denotes 200 parasites/µL cutoff. (b) Sensitivity of the Gazelle device accounting for all clinical samples and subset of samples with parasite counts less than 200 parasites/µL, grouped according to antimalarial treatment status at sampling point, further sub-grouped by pilot and validation testing phases; vertical bars represent 95% confidence intervals.